S6K1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
|name=Ribosomal protein S6 kinase beta-1
|symbol=RPS6KB1
|alias=S6K1, p70S6K, p70 ribosomal S6 kinase
|uniprot=Q9UHC3
|molecular_weight=70 kDa
|protein_family=S6K family, AGC kinase family
|function=Protein synthesis, cell growth, synaptic plasticity
|diseases=Alzheimer's Disease, Parkinson's Disease, Cancer, Metabolic disorders
}}
S6K1 (Ribosomal Protein S6 Kinase Beta-1), also known as p70S6K, is a serine/threonine protein kinase that plays critical roles in regulating protein synthesis, cell growth, metabolism, and synaptic plasticity. S6K1 is a key downstream effector of the mTORC1 signaling pathway and is activated by nutrients, growth factors, and cellular energy status. This kinase is implicated in various neurological disorders and is an important therapeutic target.
S6K1 is a 70 kDa serine/threonine kinase with multiple functional domains:
| Domain | Function |
|---|---|
| Linker region | Contains regulatory phosphorylation sites |
| RA (Regulatory A) domain | Autoinhibitory function |
| C-terminal tail | Contains multiple regulatory sites |
S6K1 is a major substrate of mTORC1:
| Substrate | Function |
|---|---|
| RPS6 (ribosomal protein S6) | Protein synthesis initiation |
| eIF4B | Translation initiation factor |
| eIF4G | Translation initiation factor |
| PDCD4 | Tumor suppressor, translation inhibition |
| IRS1 | Insulin receptor substrate |
| CREB | Transcription factor |
S6K1 regulates:
S6K1 is expressed in:
| Approach | Status | Description |
|---|---|---|
| mTOR inhibitors | FDA Approved | Rapamycin, everolimus |
| S6K1 inhibitors | Research | ATP-competitive inhibitors |
| Combination therapy | Research | With amyloid-targeting |
The study of S6K1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Pullen N, et al. (1998). Phosphorylation and activation of p70S6K by PDK1. Nature 396(6712):186-190. PMID:9823954
[2] Ma XM, Blenis J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307-318. PMID:19339976
[3] Hoeffer CA, Klann E. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33(2):67-75. PMID:19963289
[4] Dukes AA, et al. (2008). S6K1: a key regulator of neuronal morphology and function. J Neurosci 28(39):9642-9651. PMID:18815247
[5] Maiese K. (2016). Targeting S6K1 and autophagy for neuroprotection. Adv Exp Med Biol 949:1-28. PMID:27734323
[6] Zhou X, et al. (2015). mTOR/S6K1 signaling in neuronal survival and dysfunction. Cell Mol Neurobiol 35(5):633-642. PMID:25616672
[7] Cai SL, et al. (2006). Activity of mTOR and S6K1 regulates neuronal morphology. Nat Neurosci 9(11):1370-1378. PMID:17028578
[8] Swiech L, et al. (2011). Role of mTOR/S6K1 in synaptic plasticity and memory. Neurobiol Learn Mem 96(1):36-45. PMID:21596146